P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial

• Lutz Van Heek,
• Colin Stuka,
• Helen Kaul,
• Horst Müller,
• Jasmin Mettler,
• Felicitas Hitz,
• Christian Baues,
• Michael Fuchs,
• Peter Borchmann,
• Andreas Engert,
• Markus Dietlein,
• Conrad-Amadeus Voltin,
• Carsten Kobe

Affiliations

Lutz Van Heek

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Colin Stuka

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Helen Kaul

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Horst Müller

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Jasmin Mettler

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Felicitas Hitz

3 Swiss Group for Clinical Cancer Research, Bern Switzerland

Christian Baues

5 Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Michael Fuchs

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Peter Borchmann

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Andreas Engert

2 First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Markus Dietlein

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Conrad-Amadeus Voltin

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

Carsten Kobe

1 Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany